U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C20H19N3O4S.ClH
Molecular Weight 433.908
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RIVOGLITAZONE HYDROCHLORIDE

SMILES

Cl.COC1=CC2=C(C=C1)N=C(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)N2C

InChI

InChIKey=LKKAMJRUPIIUTC-UHFFFAOYSA-N
InChI=1S/C20H19N3O4S.ClH/c1-23-16-10-14(26-2)7-8-15(16)21-18(23)11-27-13-5-3-12(4-6-13)9-17-19(24)22-20(25)28-17;/h3-8,10,17H,9,11H2,1-2H3,(H,22,24,25);1H

HIDE SMILES / InChI
Molecular Formula C20H19N3O4S
Molecular Weight 397.448
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Rivoglitazone hydrochloride (CS-011) is a thiazolidinedione-derivative peroxisome proliferator–activated receptor (PPAR)-γ agonist. It has been developed as potential treatment in type 2 diabetes mellitus and was shown to decrease plasma glucose and triglyceride levels in a dose-dependent manner in animals. Phase II and III clinical studies have assessed the efficacy and safety of rivoglitazone hydrochloride in patients with type 2 diabetes mellitus.

Approval Year

Unknown
149124
PubMed

PubMed

TitleDatePubMed
A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes.
2011 Sep
Patents

Patents

05798375
2
05886014
4
06159997
3
06525220
2
06569877
2
06706746
2
06753347
2
07199139
2
07816552
2
08106079
2
JP2000001487A
2
JP2001039976A
2
JP2002220336A
2
JP2005145961A
2
JP2006182758A
2
JP2006193516A
2
JP2008162949A
2
JP2009221147A
2
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:01:44 GMT 2025
Edited
by admin
on Mon Mar 31 21:01:44 GMT 2025
Record UNII
60HQU68H8A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
2,4-THIAZOLIDINEDIONE, 5-((4-((6-METHOXY-1-METHYL-1H-BENZIMIDAZOL-2-YL)METHOXY)PHENYL)METHYL)-, MONOHYDROCHLORIDE
Preferred Name English
RIVOGLITAZONE HYDROCHLORIDE
WHO-DD  
Common Name English
CS-011 HYDROCHLORIDE
Code English
Rivoglitazone hydrochloride [WHO-DD]
Common Name English
2,4-THIAZOLIDINEDIONE, 5-((4-((6-METHOXY-1-METHYL-1H-BENZIMIDAZOL-2-YL)METHOXY)PHENYL)METHYL)-, HYDROCHLORIDE
Systematic Name English
RIVOGLITAZONE HCL
Common Name English
2,4-THIAZOLIDINEDIONE, 5-((4-((6-METHOXY-1-METHYL-1H-BENZIMIDAZOL-2-YL)METHOXY)PHENYL)METHYL)-, HYDROCHLORIDE (1:1)
Systematic Name English
Code System Code Type Description
CAS
299176-11-7
Created by admin on Mon Mar 31 21:01:44 GMT 2025 , Edited by admin on Mon Mar 31 21:01:44 GMT 2025
PRIMARY
EVMPD
SUB107720
Created by admin on Mon Mar 31 21:01:44 GMT 2025 , Edited by admin on Mon Mar 31 21:01:44 GMT 2025
PRIMARY
PUBCHEM
9889104
Created by admin on Mon Mar 31 21:01:44 GMT 2025 , Edited by admin on Mon Mar 31 21:01:44 GMT 2025
PRIMARY
SMS_ID
100000141986
Created by admin on Mon Mar 31 21:01:44 GMT 2025 , Edited by admin on Mon Mar 31 21:01:44 GMT 2025
PRIMARY
FDA UNII
60HQU68H8A
Created by admin on Mon Mar 31 21:01:44 GMT 2025 , Edited by admin on Mon Mar 31 21:01:44 GMT 2025
PRIMARY
Related Record Type Details
Structure of RIVOGLITAZONE
PARENT -> SALT/SOLVATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966